Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained prior to participation~* Able to complete adequate fundus photographs and retinal images~* Diagnosis of type 1 or 2 Diabetes Mellitus (DM) and HbA1c less than or equal to 12% at screening~* DM treatment stable for at least 3 months~* PDR diagnosis with no previous PRP treatment in the study eye~Exclusion Criteria:~* Concomitant conditions or ocular disorders in the study eye at Screening or Baseline that could compromise a response to study treatment.~* Presence of diabetic macular edema in the study eye~* Active infection or inflammation in the study eye~* Uncontrolled glaucoma (IOP greater than 25 mmHg)~* Intravitreal anti-VEGF treatment within 6 months~* Treatment with intraocular corticosteroids~* End stage renal disease requiring dialysis or kidney transplant~* Uncontrolled blood pressure~* Systemic anti-VEGF therapy at any time~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 6 mg (Type: EXPERIMENTAL): Intra-vitreal injection. 3 x q6w loading injections, followed by q12w maintenance through Week 90
- Panretinal photocoagulation laser Arm (Type: ACTIVE_COMPARATOR): Initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).